The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction
- PMID: 2171337
- DOI: 10.1016/0002-9378(90)90680-6
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction
Abstract
Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of less than 20 days was associated with prolonged overall survival (p less than 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to less than 35 U/ml within 65 days of primary operation also suggested an improved survival (p less than 0.059).
Comment in
-
Prognostic value of CA 125 and neopterin in women with ovarian cancer undergoing second-look laparotomy.Am J Obstet Gynecol. 1991 Sep;165(3):779. doi: 10.1016/0002-9378(91)90328-o. Am J Obstet Gynecol. 1991. PMID: 1892210 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
